Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia ; volume:23 ; number:1 ; day:3 ; month:3 ; year:2023 ; pages:1-7 ; date:12.2023
BMC psychiatry ; 23, Heft 1 (3.3.2023), 1-7, 12.2023
- Creator
-
Hattori, Saki
Suda, Akira
Kishida, Ikuko
Miyauchi, Masatoshi
Shiraishi, Yohko
Noguchi, Nobuhiko
Furuno, Taku
Asami, Takeshi
Fujibayashi, Mami
Tsujita, Natsuki
Ishii, Chie
Ishii, Norio
Saeki, Takashi
Fukushima, Tadashi
Moritani, Toshio
Saigusa, Yusuke
Hishimoto, Akitoyo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12888-023-04617-y
- URN
-
urn:nbn:de:101:1-2024021409225252253350
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hattori, Saki
- Suda, Akira
- Kishida, Ikuko
- Miyauchi, Masatoshi
- Shiraishi, Yohko
- Noguchi, Nobuhiko
- Furuno, Taku
- Asami, Takeshi
- Fujibayashi, Mami
- Tsujita, Natsuki
- Ishii, Chie
- Ishii, Norio
- Saeki, Takashi
- Fukushima, Tadashi
- Moritani, Toshio
- Saigusa, Yusuke
- Hishimoto, Akitoyo
- SpringerLink (Online service)
Other Objects (12)
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report
Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan
Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report
Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Aripiprazole as protector against COVID-19 mortality
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report
Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan
Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report
Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Aripiprazole as protector against COVID-19 mortality
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report
Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan
Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report
Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia